![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EMA Grants BioMarin Priority Medicine Support for Hemophilia Therapy
EMA Grants BioMarin Priority Medicine Support for Hemophilia Therapy
February 10, 2017
BioMarin received a priority medicine designation from the European Medicines Agency for its gene therapy treatment for hemophilia A.
The therapy, BMN 270, is designed to alter a genetic problem by adding a corrected copy of the defective gene. In this case, it would be factor VIII, a clotting protein.
Upcoming Events
-
21Oct